Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression : a placebo-controlled, double-blind, randomised trial in the UK

Thumbnail
Name:
Browning 2025 1-11.pdf
Size:
953.9Kb
Format:
PDF
Download
Author
Browning, Michael
Cowen, Philip J
Galal, Ushma
Baldwin, Ashley
Cleare, Anthony J
Evans, Jonathan
Huys, Quentin J M
Kessler, David
Kurkar, Micheal
Nixon, Neil
Keyword
Major depressive disorder
Depression
Drug therapy
Date
2025

Metadata
Show full item record
DOI
10.1016/S2215-0366(25)00194-4
Publisher's URL
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00194-4/fulltext
Abstract
BackgroundAbout 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used. Pramipexole might usefully augment antidepressant medication in such cases of treatment-resistant depression, but data on its effects and tolerability are scarce. We aimed to assess the efficacy and tolerability of pramipexole augmentation of ongoing antidepressant treatment, over 48 weeks, in patients with treatment-resistant depression.
Citation
Browning, M., Cowen, P. J., Galal, U., Baldwin, A., Cleare, A. J., Evans, J., Huys, Q. J. M., Kessler, D., Kurkar, M., Nixon, N., et al. (2025). Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression : a placebo-controlled, double-blind, randomised trial in the UK. The Lancet Psychiatry, 12 (8), pp.579-589.
Publisher
Elsevier
Type
Article
URI
http://hdl.handle.net/20.500.12904/19735
Note
2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Collections